Announcement of Successful Completion of the Translational Science Summit and Andu Bioscience's 5th Anniversary Celebration
The Translational Science Summit and AMADOR BIOSCIENCE’s 5th Anniversary Celebration, Hosted by AMADOR BIOSCIENCE, Concluded Successfully.
Dr. Li Ming Shao, Distinguished Professor at the School of Pharmacy, Fudan University; Dr. Xin Gao, CEO of Immune Ark; Dr. Haifeng Bao, CEO of Baikai Medicine; Dr. Zhenwei Miao, CEO of Innovent Biologics; Dr. Yuan Fang, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences; Dr. Peng Fu, Assistant President of Saifu Pharmaceutical; Dr. Zhaokui Wan, CEO of LinkChem Therapeutics; Dr. Zhongmin Ma, CEO of Ruifulong Biotechnology; Dr. Jiansong Tong, CEO of Saiyuan Biotechnology; Dr. Qiying Lu, CMO of Yiming AngkeNearly 20 leading experts from the biomedical academia, medical community, and industry attended to share their insights, engaging in intellectual exchanges on translational science with a focus on the research and development of oncology drugs and therapies.
Group Photo of Guests
This forum is organized byDr. Wang Bing, Chairman and CEO of AMADOR BIOSCIENCE, presided over the event and delivered the opening remarks., he stated in his address that since the founding of Amador Bioscience in 2018,AMADOR BIOSCIENCE has always been committed to leveraging its professional expertise, industry reputation, and business ecosystem advantages to provide international-standard services to biopharmaceutical companies.AMADOR BIOSCIENCE has established multiple sites across three continents, with three GLP laboratories already in operation. Its business covers one-stop CRO services focused on translational and early-stage clinical development, including clinical pharmacology, bioanalysis and biomarkers, regulatory affairs, biostatistics, and clinical development.
In his address, Dr. Wang Bing stated that all achievements over the past five years would not have been possible without the trust and support of employees, customers, peers in the pharmaceutical and academic communities, and investment institutions for Amador Bioscience.Looking ahead, AMADOR BIOSCIENCE will continue to evolve as a next-generation CRO to meet growing clinical development needs. We will further advance our digital and intelligent infrastructure, integrate proven technologies to accelerate drug development, and uphold our core cultural values of excellence, collaboration, courage, and integrity. Striving to become the most diverse platform-based CRO, we will broaden our “bridge” to help more drugs enter global markets and make more meaningful contributions to the industry.
Dr. Wang Bing, Chairman and CEO of AMADOR BIOSCIENCE
Dr. Wang Bing stated that translational science serves as a bridge linking basic research and clinical practice, and is also key to new drug development. He expressed the hope that this forum would deepen understanding of accelerating clinical translation, and facilitate in-depth discussions on the challenges and opportunities in new drug technology development and clinical translation.
Dr. Shaoli Ming, Distinguished Professor at Fudan University, first shared insights on the challenges and opportunities in China's biomedical innovation.Drawing on multiple datasets, he led attendees through a review of how China’s economic development and evolving national policies have propelled the biopharmaceutical industry to new heights over the past two decades. He emphasized that innovation quality is paramount in the development of innovative drugs, and that fostering innovation requires optimizing the combination of ecosystem elements, strengthening breakthroughs in basic research and their translation, accelerating the restructuring of the industry, and placing greater emphasis on talent.
Prof. Li-Ming Shao, Fudan University
Dr. Gao Xin, CEO of Immune ArkShared the challenges encountered and solutions implemented in the development of immuno-oncology antibody therapeutics, illustrated through case studies.
Dr. Gao Xin, Chairman and CEO of Immune Ark
Dr. Hai Feng Bao, Baikai Biotech“ADC Innovation and R&D from the Perspective of Translational Science”: A Detailed Discussion on Key Considerations of Translational Science Strategies, as Well as Their Applications, Strategic Approaches, and Case Studies in ADC Drug Development
Dr. Haifeng Bao, CEO of Baikai Biologics
Dr. Miao Zhenwei, CEO of Innovent BiologicsThe presentation focused on innovative drug development in the fields of ADC and ACC, with an emphasis on the development strategy for the ACC technology platform.
Dr. Miao Zhenwei, CEO of Innovent Biologics
Dr. Yuan Fang, National Cancer Center / Cancer Hospital, Chinese Academy of Medical SciencesFrom the perspective of an oncologist, this presentation outlines the current state of genuine clinical needs, interprets regulatory policies, and shares insights on how to closely integrate new drug development with clinical practice.
Fang Yuan, M.D.National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences
Dr. Fu Peng, Assistant President of PharmaronHe addressed topics related to the preclinical research of gene therapy drugs, elaborating on three aspects: considerations for non-clinical evaluation, key focus areas, and case studies.
Dr. Peng Fu, Assistant President of CytoMed
Roundtable Discussion: The Application of Translational Science in New Drug Development
This Roundtable DiscussionModerated by Dr. Hao Yuwen, Senior Vice President of Global Regulatory Affairs at Amador Bioscience, the discussion featured Dr. Zhaokui Wan, CEO of LinkHealth; Dr. Zhongmin Ma, CEO of Ruifulong Biotech; Dr. Jiansong Tong, CEO of Saiyuan Biologics; and Dr. Qiying Lu, CMO of ImmuneOnco.Discussion on the Application of Translational Science in New Drug Development: An In-Depth Exploration of How to Accelerate R&D Progress and Improve Success Rates from the Perspectives of Biomarkers, Target Pathways, Dose Selection, and Clinical Trial Design
Happy Hour: AMADOR BIOSCIENCE 5th Anniversary Celebration
Ms. Chen Xiaomin, COO of AMADOR BIOSCIENCE
About Amador Bioscience
AMADOR BIOSCIENCE is a globally leading next-generation CRO specializing in translational and clinical development.
As the preferred partner for successful innovative drug development, AMADOR BIOSCIENCE provides end-to-end services compliant with international standards for new drug development in China, Europe, and the United States. These services include translational and quantitative pharmacology, bioanalysis and biomarkers, regulatory submissions, biostatistics, and clinical development. The company offers comprehensive clinical development strategies and execution from preclinical stages to market launch, scientifically optimizing dose selection, target selection, and patient selection. By integrating a globally unified technical platform, management system, and quality standards, AMADOR BIOSCIENCE enhances the efficiency and success rate of new drug R&D. Its client base ranges from leading startup biotech companies to large multinational pharmaceutical enterprises. To date, the AMADOR team has successfully completed over 210 marketing authorization submissions (NDA, BLA, MAA) for domestic and international clients in China, the United States, Europe, and Japan.
Amador Bioscience has established operational facilities in multiple locations worldwide, including Pleasanton, CA; Ann Arbor, MI; and Germantown, MD in the United States; Hangzhou, Shanghai, and Beijing in China; and Limburg, Belgium in Europe.